Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Researcher Adapting New Technologies for Fighting Worm Infections

By Drug Discovery Trends Editor | October 27, 2014

Recent breakthroughs may pave the way for vaccines and new drugs for those infected by parasitic helminths. These flatworms, including tapeworms that cause hydatid diseases and neurocysticercosis, liver flukes, and blood flukes (schistosomes), infect more than 300 million people and cause approximately four million disability-adjusted life years lost due to chronic illness and death each year.

Paul Brindley, Ph.D., professor of microbiology, immunology, and tropical medicine, and scientific director of the Research Center for Neglected Diseases of Poverty at the George Washington University School of Medicine and Health Sciences, co-authored a perspective in the journal Science, calling for researchers to adapt new technologies to research these neglected pathogens.

“It took several years of work to sequence the genomes of the major species of flatworm parasites. However, now that we have this information, we can focus on genes of interest,” said Brindley. “Even now, researchers are deploying retroviruses for transgenesis and genome editing of flatworm parasites to identify new ways to cure people who are afflicted by these infections. This is a major focus of research at the GW Research Center for Neglected Diseases of Poverty, which demonstrates the potential of what can already be done with new technologies.”

In addition to breakthroughs in manipulation of genomes of these flatworm pathogens, as well as revolutionary strategies such as harnessing the bacterial clustered regulatory interspaced short palindromic repeats, known as CRISPR, isolation of organs of the parasites, characterization of stem cells of these worms, and advances in primary cell culture are expanding the molecular toolkit available to scientists. These resources are now all available to the scientific community. These technologies have been in use in mammals and model species for some time, but comparable research on neglected tropical disease helminth parasites has lagged far behind.

Brindley, along with his co-authors Karl Hoffman, Ph.D., professor of parasitology and leader of the Animal and Microbial Sciences Research Theme at Aberystwyth University, and Mathew Berriman, Ph.D., program leader for parasite genomics at the Wellcome Trust Sanger Institute, encourage researchers to take advantage of these break-through techniques to address long-asked questions about the pathogenesis, developmental biology, and evolution of flatworm parasites.

“Because of issues like global warming and migrations of people, these diseases are spreading,” said Brindley. “While historically considered as tropical diseases, infections by these parasites have recently expanded to Western Europe, including Corsica, and expansions to other continents are expected. Current drugs, in use for the last 40 years, are unsustainable and in danger of over-reliance, unless new interventions are found.”

Date: October 27, 2014

Source: George Washington University


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE